JP2010248169A - Water-in-oil type emulsion skin lotion - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a water-in-oil type emulsion skin lotion containing a liquid agent having polarity such as Ufenamate or the like which is excellent in emulsion stability, agent stability and also has occlusive characteristics but is not sticky and is excellent in usability. <P>SOLUTION: The water-in-oil type emulsion skin lotion contains compositions (a) to (f) shown below: (a) 10-20 mass% of a liquid oil content; (b) 1-10 mass% of one sort or two sorts or more of liquid agents among Ufenamate, diphenhydramine, Crotamiton; (c) POE (4-6) hydrogenated castor oil; (d) a sorbitan fatty acid ester; (e) polyether-modified silicone and (f) water, provided that components (c):(d):(e)=30-80:10-45:5-55 (mass ratio) and total compounded amount of components (c) to (e) is 0.8-8.0 mass%. Furthermore; (g) a dextrin fatty acid ester; and (h) polyethylene glycol having a mass-average molecular weight of 4,000-20,000 may be compounded. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a water-in-oil type emulsified skin external preparation. More specifically, it is a system containing a liquid drug such as ufenamate, which is excellent in emulsification stability and drug stability, and has a skin occlusive property that suppresses excessive water volatilization from the skin surface. It is related with the water-in-oil type emulsified skin external preparation which is excellent in water.

  Conventionally, a non-aqueous petrolatum ointment using petrolatum is known as a skin external preparation with high skin occlusive properties. However, petrolatum ointment has the disadvantage of poor stretch and stickiness. On the other hand, the oil-in-water emulsified cream does not feel sticky, but is inferior in occlusion.

  Therefore, a water-in-oil emulsifying base is considered as a base that has higher skin occlusiveness than oil-in-water emulsifying systems and does not feel sticky like petrolatum ointment. Pharmaceutical creams are difficult to formulate, and when a surfactant that can be used in pharmaceutical preparations (for example, sorbitan sesquiolate, which is a lipophilic surfactant) is used, hardness does not appear and the stability of the formulation is guaranteed. There was a problem that I could not. In addition, there are restrictions on the raw materials used for pharmaceutical use, and it has been difficult to design a stable formulation. In general, when a liquid drug with polarity (for example, ufenamate known as a non-steroidal anti-inflammatory agent, diphenhydramine known as an antihistamine, crotamiton known as an antipruritic agent, etc.) is mixed with an emulsifying base, the formulation is stable. However, this is particularly noticeable when these liquid drugs are added to a water-in-oil emulsion base. For this reason, there are almost no water-in-oil emulsion preparations for medical use or general medicinal use, and it is extremely difficult to add a polar liquid drug to a water-in-oil emulsion composition that is expected to have an appropriate occlusive property. is there.

  In order to stably mix such a liquid drug, for example, in Japanese Patent Application Laid-Open No. 2001-181166 (Patent Document 1), an oil-soluble drug (Ufenamate or the like) having an IOB value of 0.1 to 2, carbon in the molecule Lipophilic emulsifier having two or more hydrophobic groups containing a carbon chain of several 8 or more (for example, polyglycerol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene (hereinafter also referred to as “POE”) sorbite fatty acid ester, POE hydrogenated castor oil Etc.) containing a water-in-oil emulsified skin external preparation composition. However, in Patent Document 1, only one month (25 ° C., 40 ° C.) of the emulsion stability is evaluated for storage stability, and for four months at a high temperature (50 ° C.) as in the present invention described later. Whether the storage stability can be maintained for a long period of time has not been studied. In addition, the drug residual rate in the preparation after storage at high temperature has not been studied.

  Japanese Patent Application Laid-Open No. 2006-335735 (Patent Document 2) describes a water-in-oil emulsion composition comprising an oil, a nonionic surfactant having an HLB value of 8 or less, an electrolyte, and a water-soluble polyhydric alcohol. ), It is described that a medicinal component can be further contained (claim 8, [0018], etc.). However, Patent Document 2 does not describe a specific composition in which a liquid drug such as ufenamate, which has been conventionally difficult to be stably blended in a water-in-oil emulsion system, is described. There is no description or suggestion that the purpose is to stably mix a drug in the system for a long period of time. There is no description or suggestion about the blending of polyether-modified silicone.

  Japanese Patent Application Laid-Open No. 2008-1237306 (Patent Document 3) discloses a water-in-oil emulsified cosmetic containing a silicone surfactant, an oil agent, an oil gelling agent, a water-soluble polymer, and 61 to 98% by mass of water. However, it describes that it has a moisturizing effect, is not sticky, and has stability (uniformity, separation, etc.), and further describes that a nonionic surfactant can be blended therein (claims). Range column). Polyether-modified silicones are exemplified as the silicone surfactant ([0009]), palmitic acid fatty esters and the like are described as the oil gelling agent ([0027]), and POE as the nonionic surfactant. Hardened castor oil, sucrose fatty acid ester, and the like are described, and it is described that a suitable blending amount of these nonionic surfactants is 0.05 to 5% by mass ([0049] to [0050]). However, Patent Document 3 relates to cosmetics, and there is no description of a specific composition containing a liquid drug such as ufenamate, which has been conventionally difficult to be stably added to a water-in-oil emulsion system. Further, there is no description or suggestion that the purpose is to stably blend such a highly polar liquid drug into the system for a long period of time. In Examples of Patent Document 3, a cationic cross-linked copolymer is used as the water-soluble polymer, but such a compound is not used in the present invention.

  Japanese Examined Patent Publication No. 3-56776 (Patent Document 4) discloses a water-in-oil emulsion composition containing a specific nonionic surfactant, a liquid oil, a polyethylene glycol having a molecular weight of 2000 to 300,000, and a predetermined amount of water. The product is described, and the medicinal agent is “lined as one line” as an optional additive component (page 3, column 6, line 12). However, in Patent Document 4, there is no description of a specific composition containing a medicinal agent, and a liquid drug such as ufenamate, which has been conventionally difficult to be stably added to a water-in-oil emulsion system, is stably added. There is no mention or suggestion of any purpose.

JP 2001-181166 A JP 2006-335735 A JP 2008-1237306 A Japanese Examined Patent Publication No. 3-56776

  The present invention has been made in view of the above-described conventional circumstances, and is a system containing a liquid drug having a polarity such as ufenamate, which is excellent in emulsification stability, drug stability, and occlusive, but not sticky. An object of the present invention is to provide a water-in-oil emulsified skin external preparation having excellent usability.

In order to solve the above problems, the present invention provides a water-in-oil emulsified skin external preparation containing the following components (a) to (f).
(A) 10 to 20% by mass of liquid oil,
(B) 1 to 10% by mass of one or more liquid agents selected from ufenamate, diphenhydramine, and crotamiton,
(C) polyoxyethylene (4-6 mol addition) hydrogenated castor oil,
(D) sorbitan fatty acid ester,
(E) a polyether-modified silicone, and (f) water.

  However, in the above, (c) component: (d) component: (e) component = 30-80: 10-45: 5-55 (mass ratio), and (c) component, (d) component, and (e) ) The total compounding amount of the components is 0.8 to 8.0% by mass.

  Moreover, this invention provides the said water-in-oil type emulsion skin external preparation whose component (e) is a compound shown to following formula (I).

(Wherein R ₁ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; r represents a number of 50 to 60; u represents a number of 2 to 5; a represents 8 to 10; b represents Represents a number from 0 to 35.)

  The present invention also provides the water-in-oil emulsified skin external preparation, wherein the component (b) is a liquid drug comprising ufenamate and diphenhydramine.

  The present invention further provides the water-in-oil type emulsified skin external preparation described above, further comprising (g) a dextrin fatty acid ester.

  The present invention further provides the above-mentioned water-in-oil type emulsified skin external preparation further comprising (h) polyethylene glycol having an average mass molecular weight of 4,000 to 20,000.

  According to the present invention, a system comprising a liquid drug having polarity such as ufenamate, which is excellent in emulsification stability, drug stability, occlusion, non-sticky and excellent in usability An external preparation is provided.

It is a triangular figure which shows the relationship between the composition (mass%) of POE (5) hydrogenated castor oil in this invention, sorbitan sesquioleate, and polyether modified silicone ("KF-6017P"), and emulsion stability.

  Hereinafter, the present invention will be described in detail.

  The liquid oil component as the component (a) in the present invention refers to a fluid oil component that does not volatilize at room temperature (25 ° C.). Specifically, for example, hydrocarbon oils such as liquid paraffin, squalane, olefin oligomer, light isoparaffin (= light liquid paraffin); 2-ethylhexanoic acid triglyceride, 2-ethylhexanoic acid cetyl, 2-ethylhexanoic acid pentaerythritol , Ester oils such as 2-ethylhexanoic acid trimethylolpropane, 2-ethylhexyl palmitate, isocetyl isononanoate, isopropyl myristate, cetyl 2-ethylhexanoate, diethyl sebacate, diethyl adipate; jojoba oil, olive oil, macadamia nut oil , Cottonseed oil, tea seed oil, safflower oil, rice bran oil, and other natural plant oils; decamethylpentacyclosiloxane, octamethyltetracyclosiloxane, dimethylpolysiloxane, methylphenylpolysiloxane Which silicone oil, and the like, it is of course not limited to these examples. In the present invention, hydrocarbon oils, ester oils, and silicone oils are preferably used from the viewpoints of compatibility with the component (b), usability, and the appearance of the external preparation. (A) A component can use 1 type (s) or 2 or more types.

  (A) The compounding quantity of a component is 10-20 mass% in this invention skin external preparation whole quantity. If it is less than 10% by mass, the compatibility with the component (b) is poor, the polarity of the oil phase component as a whole is relatively high, and the emulsifiability is unfavorable, and the internal phase ratio is increased. It becomes high and is not preferable in terms of usability and appearance. On the other hand, if it exceeds 20% by mass, the internal phase ratio decreases and the hardness decreases, which is not preferable in terms of stability.

Component (b) is an oil-soluble liquid drug component having polarity. In the present invention, one or more selected from ufenamate, diphenhydramine, and crotamiton are used. Ufenamate is known as a non-steroidal anti-inflammatory agent and is represented by the chemical formula C ₁₈ H ₁₈ F ₃ NO ₂ , and the chemical name is butyl O-[[3- (trifluoromethyl) phenyl] amino] -benzoate. Diphenhydramine is known as an antihistamine and is represented by the chemical formula C ₁₇ H ₂₁ NO. Crotamiton is known as an antipruritic agent and is represented by the chemical formula C ₁₃ H ₁₇ NO.

  (B) The compounding quantity of a component is 1-10 mass% in this invention skin external preparation whole quantity, Preferably it is 1-6 mass%. If the amount is less than 1% by mass, the medicinal effect of the component (b) cannot be sufficiently exhibited. On the other hand, if it exceeds 10% by mass, the viewpoint of effective use of resources and the stability of the preparation are somewhat unstable, which is not preferable.

  In the present invention, the following (c) component, (d) component, and (e) component are combined and blended as a nonionic surfactant.

  (C) A component is POE (4-6) hydrogenated castor oil. If the POE addition mole number is less than 4, the lipophilicity is too high, and the product is substantially not on the market. On the other hand, the POE addition mole number exceeds 6 (as a marketed product “Nikkor HCO-10” (Nikko Chemicals) Etc.) are not preferred because the emulsification becomes unstable. Component (c) is commercially available, for example, as “Nikkor HCO-5” (manufactured by Nikko Chemicals Co., Ltd.), “EMALEX HC-5” (manufactured by Nippon Emulsion Co., Ltd.), and the like. (C) A component can use 1 type (s) or 2 or more types.

  The component (d) is sorbitan fatty acid ester. In the component (d), the fatty acid residue preferably contains an oleic acid residue, an isostearic acid residue, or a lauric acid residue from the viewpoint of stability. Specific examples of the component (d) include sorbitan sesquioleate and sorbitan sesquiisostearate. The component (d) is, for example, “Nikkor SO-15R”, “Nikkor SI-15R” (manufactured by Nikko Chemicals Co., Ltd.), “EMALEX SPO-150”, “EMALEX SISP-150” (manufactured by Nippon Emulsion Co., Ltd.). Etc. are commercially available. (D) 1 type (s) or 2 or more types can be used for a component.

  The component (e) is a polyether-modified silicone. In the present invention, in particular, the following formula (I)

(Wherein R ₁ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; r represents a number of 50 to 60; u represents a number of 2 to 5; a represents 8 to 10; b represents A polyether-modified silicone represented by the formula (0 to 35) is preferably used. In formula (I), R ₁ is preferably a hydrogen atom, and b is preferably 0.

  Polyether-modified silicones are commercially available, for example, as “KF-6017P” (manufactured by Shin-Etsu Chemical Co., Ltd.), “SS-2910” (Toray Dow Corning). (E) 1 type (s) or 2 or more types can be used for a component.

  In the present invention, the component (c), the component (d), and the component (e) are blended at a ratio of 30 to 80:10 to 45: 5 to 55 (mass ratio). Preferably it is 40-80: 10-45: 5-50 (mass ratio), More preferably, it is 45-80: 10-45: 5-30 (mass ratio). By blending component (c), component (d), and component (e) in the above proportions, they are emulsified even after storage for 4 months at moderate hardness, excellent formulation stability, and high temperature (50 ° C). Stability can be maintained.

  In addition, the triangular figure which shows the relationship between the composition (mass%) of 3 components, (c) component, (d) component, and (e) component, and emulsion stability is shown in FIG. Components other than these three components were blended components and blended amounts shown in Example 1 described later, and the blending ratio of the three components was changed in the system. (C) component is POE (5) hydrogenated castor oil ("Nikkor HCO-5"; manufactured by Nikko Chemicals Co., Ltd.), and (d) component is sorbitan sesquioleate ("Nikkor SO-15R"; Nikko Chemicals Co., Ltd.) )) And PEG-10 dimethicone ("KF-6017P"; manufactured by Shin-Etsu Chemical Co., Ltd.) were used as the component (e). In FIG. 1, the region surrounded by the cross diagonal lines is the scope of the present invention.

  In this invention, the total compounding quantity of (c) component, (d) component, and (e) component is 0.8-8.0 mass%, Preferably it is 1.0-6.0 mass%. If the total blending amount of the three components is less than 0.8% by mass, the preparation cannot be emulsified, whereas if it exceeds 8.0% by mass, the amount becomes unnecessary for emulsification.

  The component (f) is water. The amount of water is preferably 50 to 80% by mass, more preferably 55 to 75% by mass, based on the total amount of the external preparation for skin of the present invention. If it is less than 50% by mass, the internal phase ratio is low and sufficient hardness cannot be obtained and the stability of the preparation tends to be poor. On the other hand, if it exceeds 80% by mass, the internal phase ratio becomes high and preparation of an external preparation is difficult. There is a tendency to become difficult.

  In the present invention, by blending the components (a) to (f) as essential components, the component (b), which is an oil-soluble drug having polarity, can be stably blended, and the emulsion stability of the system can be improved. In addition, it is excellent in feeling of use (non-sticky) while being excellent in blocking properties. The component (c), component (d) and component (e) are nonionic surfactant components, but in the present invention, these three components are not used in combination, and a stability effect cannot be obtained. Generally, when two or more kinds of polar oil-soluble drugs are combined and formulated, it is difficult to guarantee the stability of the preparation. However, in the present invention, two kinds of drugs are combined as the component (b) (for example, ufenamate and diphenhydramine). Even if it is a case where it mix | blends, stability of a formulation can be ensured by combined use with (a) component and (c)-(f) component.

  In this invention, you may mix | blend (g) dextrin fatty acid ester further if desired. (G) By mix | blending a component, an external oil phase can be thickened and the high temperature stability effect of an external preparation can be improved further. The dextrin fatty acid ester as component (g) is an ester of dextrin or reduced dextrin and a higher fatty acid. The average dextrin or reduced dextrin having an average sugar polymerization degree of 3 to 100 is preferably used. The higher fatty acid is preferably a saturated fatty acid having 8 to 16 carbon atoms. Specific examples include octanoic acid, lauric acid, myristic acid, and palmitic acid. Component (g) is commercially available as “Leopard KL”, “Leopard MKL”, “Leopard TT” (all of which are manufactured by Chiba Flour Milling Co., Ltd.), and the like, and these can be used preferably. (G) A component can use 1 type (s) or 2 or more types.

  (G) When mix | blending a component, it is preferable that the compounding quantity shall be 3.0 mass% or less in this invention skin external preparation whole quantity, More preferably, it is 0.2-1.2 mass%.

  In the present invention, (h) polyethylene glycol having an average mass molecular weight of 4,000 to 20,000, preferably 6,000 to 10,000 may be further blended as desired. (H) By mix | blending a component, the growth of emulsified particle can be suppressed by prevention of Ostwald dry planning and the stability effect of an external preparation can be improved further. Polyethylene glycol is a name listed on the makeup base and is called a macrogol in the name listed in JP, both of which refer to the same substance.

  (H) When mix | blending a component, 0.5-5.0 mass% is preferable in the total amount of this invention external preparation for skin, More preferably, it is 1.0-3.0 mass%.

  The water-in-oil emulsified skin external preparation of the present invention can be prepared by a conventional method, and the emulsification method is not particularly limited. For example, the aqueous phase (inner phase) and the oil phase (outer phase) are each heated to about 70 ° C., the heated aqueous phase is gradually added to the oil phase, emulsified with an emulsifier, and then brought to room temperature. Although the method of cooling etc. is mentioned, it is not limited to this. In the present invention, the aqueous phase (inner phase) is preferably 50 to 80% by mass, more preferably 55 to 75% by mass, based on the total amount of the external preparation for skin. The aqueous phase contains a water-soluble component (glycerin, 1,3-butylene glycol, polyethylene glycol 6000, etc.) in addition to the component (f). By making the amount of the aqueous phase blended within the above range, the sticky feeling can be more effectively suppressed.

  The water-in-oil type emulsified skin external preparation of the present invention includes other optional additives usually used for external skin preparations such as cosmetics and pharmaceuticals within a range not impairing the effects of the present invention, such as fats and oils, waxes, carbonized Hydrogen oil, petrolatum, higher alcohol, higher fatty acid, surfactant, UV absorber, sequestering agent, lower alcohol, polyhydric alcohol, powder component, sugar, amino acid and salt thereof, organic amine, polymer emulsion, pH adjustment Agents, skin nutrients, vitamins, antioxidants, antioxidant auxiliaries, fragrances and the like can be appropriately blended as necessary.

  Other compoundable ingredients include, for example, preservatives (methyl paraben, ethyl paraben, butyl paraben, etc.); anti-inflammatory agents (eg, glycyrrhizic acid and derivatives thereof, glycyrrhetinic acid and derivatives thereof, salicylic acid and derivatives thereof, hinokitiol, zinc oxide, Allantoin, etc.); whitening agent (eg, Yukinosita extract, arbutin, etc.); various extracts (eg, buckwheat, auren, shikon, peonies, assembly, birch, sage, loquat, carrot, aloe, mallow, iris, grape, yokuinin) , Loofah, lily, saffron, senkyu, ginger, hypericum, onionis, garlic, pepper, chimpi, toki, seaweed, etc.), activator (for example, royal jelly, photosensitizer, cholesterol derivative, etc.); Nucleic acid wallenylamide, nicotinic acid benzyl ester, nicotinic acid β-butoxyethyl ester, capsaicin, gingerone, cantalis tincture, ictamol, tannic acid, α-borneol, nicotinic acid tocopherol, tocopherol acetate, inositol hexanicotinate, cyclandrate, Cinnarizine, trazoline, acetylcholine, verapamil, cephalanthin, γ-oryzanol, etc.); antiseborrheic agents (eg, sulfur, thianthol, etc.); anti-inflammatory agents (eg, tranexamic acid, thiotaurine, hypotaurine, etc.). However, it is not limited to these examples.

  Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited thereto. Unless otherwise specified, all the amounts are mass%. In the following examples, POE (5) hydrogenated castor oil is “Nikkor HCO-5” (manufactured by Nikko Chemicals), and sorbitan sesquioleate is “Nikkor SO-15R” (manufactured by Nikko Chemicals). The polyether-modified silicone used was “KF-6017P” (manufactured by Shin-Etsu Chemical Co., Ltd.), which is PEG-10 dimethicone, and “Leopearl KL” (Chiba Flour Milling Co., Ltd.) was used as the dextrin palmitate.

  First, the test method and evaluation method used in this example will be described.

[hardness]
The hardness (preparation date. 25 ° C.) of each sample was measured. Hardness was shown by the breaking load (g) by Curdmeter.Max Me-500 (made by I. techno Engineering). The hardness is preferably about 5 to 30 as a cream base.

[Emulsification stability]
Each sample was left in a thermostat at 50 ° C. for 4 months, and the appearance was visually observed for the emulsion stability.

(Examples 1-4, Comparative Examples 1-2)
Using the drug-containing emulsified skin external preparation of the composition shown in Table 1 below as a sample, hardness and emulsification stability were evaluated according to the above test method and evaluation criteria. The results are shown in Table 1.

  As is apparent from the results in Table 1, in Examples 1 to 4, the emulsion stability was excellent even after 4 months at 50 ° C., but POE with a large number of moles of POE added instead of component (c) (10 ) In Comparative Example 1 using hydrogenated castor oil, emulsification was poor, and in Comparative Example 2 lacking the component (e), separation occurred in 2 months, and good emulsification stability was not obtained. In addition, Examples 1-4 were all good occlusion and a feeling of use (not sticky).

(Examples 5 to 9, Comparative Example 3)
Using the drug-containing emulsified skin external preparation having the composition shown in Table 2 below as a sample, the hardness and emulsification stability were evaluated according to the above test method and evaluation criteria. The results are shown in Table 2.

  As is apparent from the results in Table 2, in Examples 5 to 9, the emulsion stability was excellent even after 4 months at 50 ° C. On the other hand, in Comparative Example 3, for example, when compared with Example 6, the components (c), (d), and (e) all have the same blending ratio, but the total amount of these three components is Example 6. In the lower limit value range of the present invention, although the hardness was low, emulsification stability was obtained, but in Comparative Example 3, since the total amount of the three components was lower than the present range, emulsification was not performed. In addition, all of Examples 5 to 9 had good occlusion and use feeling (not sticky).

(Examples 10-13, Comparative Examples 4-7)
Using the highly polar drug-containing emulsified skin external preparation having the composition shown in Table 3 below as a sample, the hardness and emulsification stability were evaluated according to the above test method and evaluation criteria. The results are shown in Table 3.

  As is apparent from the results in Table 3, in Examples 10 to 13, the emulsion stability was excellent even after 4 months at 50 ° C., but any one of the components (c), (d), and (e) Comparative Examples 4 to 7 lacking the above were not emulsified uniformly or separated in several weeks to several months, and good emulsification stability could not be obtained. In addition, all Examples 10-13 were favorable obstruction | occlusion property and usability (not sticky).

(Examples 14 to 16)
Using the drug-containing emulsified skin external preparation having the composition shown in Table 4 below as a sample, the drug residual rate was evaluated. The results are shown in Table 4.

[Drug remaining rate]
Each sample shown in the following Table 4 was put in a glass bottle, and the drug residual ratio after being stored for 2 months in a thermostatic bath at 0 ° C. or 50 ° C. was measured and evaluated.

  As is clear from the results in Table 4, in any of Examples 14 to 16, the drug residual rate was extremely high even after 2 months at 0 ° C and 50 ° C. In some cases, the residual rate of the drug exceeds 100%, but this is because when preparing a calibration curve for the drug alone, the prescription is complicated in actual measurement, and the work such as extraction and coexisting substances This is because it may exceed 100% in calculation. In such a case, the value at 0 ° C., which is considered to be stable, is assumed to be 100%, and the remaining amount at 50 ° C. is often displayed.

  According to the present invention, a system comprising a liquid drug having polarity such as ufenamate, which is excellent in emulsification stability, drug stability, occlusion, non-sticky and excellent in usability An external preparation is provided.

Claims (5)

A water-in-oil emulsified skin external preparation containing the following components (a) to (f):
(A) 10 to 20% by mass of liquid oil,
(B) 1 to 10% by mass of one or more liquid agents selected from ufenamate, diphenhydramine, and crotamiton,
(C) polyoxyethylene (4-6 mol addition) hydrogenated castor oil,
(D) sorbitan fatty acid ester,
(E) a polyether-modified silicone, and (f) water.
However, in the above, (c) component: (d) component: (e) component = 30-80: 10-45: 5-55 (mass ratio), and (c) component, (d) component, and (e) ) The total compounding amount of the components is 0.8 to 8.0% by mass. (E) The water-in-oil type emulsified skin external preparation of Claim 1 whose component is a compound shown to following formula (I).

(Wherein R ₁ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; r represents a number of 50 to 60; u represents a number of 2 to 5; a represents 8 to 10; b represents Represents a number from 0 to 35.)   (B) The water-in-oil type emulsified skin external preparation of Claim 1 or 2 whose component is a liquid chemical | medical agent which consists of ufenamate and diphenhydramine.   The water-in-oil emulsified skin external preparation according to any one of claims 1 to 3, further comprising (g) a dextrin fatty acid ester.   The water-in-oil emulsified skin external preparation according to any one of claims 1 to 4, further comprising (h) polyethylene glycol having an average mass molecular weight of 4,000 to 20,000.

Images